Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma

FDA decision expected by August 2, 2026 FDA decision expected by August 2, 2026

Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.